Randomized Trialhigh evidence
Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial.
Lancet (London, England)·June 20, 2026·PMID 42259343
Why it mattersElecoglipron is an oral small-molecule GLP-1 agonist without food or fluid restrictions, potentially offering a convenient alternative to injectable or peptide-based oral GLP-1 therapies for metabolic disease.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled